The startup offers a liquid biopsy genome analysis service that utilizes mutation amplification techniques combined with next-generation sequencing to detect cancer at an early stage. This technology enables healthcare professionals to provide personalized treatment plans, significantly improving patient outcomes by identifying cancer before it progresses.
Funding
Funding not disclosed
Founders
Product
Problem
Early cancer detection is crucial for improving patient outcomes, but traditional methods like tissue biopsies are invasive and may not be feasible for regular screening. Detecting cancer at an early stage through non-invasive methods remains a significant challenge.
Solution
This startup provides a liquid biopsy genome analysis service designed for early cancer detection. The core technology leverages mutation amplification techniques coupled with next-generation sequencing (NGS) to identify cancer biomarkers from blood samples. By analyzing circulating tumor DNA (ctDNA), the platform aims to detect cancer at an earlier stage than conventional diagnostic methods. This non-invasive approach enables healthcare professionals to gain insights into a patient's cancer status without the need for invasive procedures. The resulting data can then be used to inform personalized treatment plans and improve patient outcomes.
Target Audience
The primary target audience includes oncologists, pathologists, and healthcare providers seeking advanced diagnostic tools for early cancer detection and personalized treatment planning.
Features
- Mutation amplification techniques to enhance the detection of rare cancer biomarkers in liquid biopsies.
- Next-generation sequencing (NGS) for comprehensive genomic analysis of circulating tumor DNA (ctDNA).
- Non-invasive blood draw procedure, eliminating the need for surgical biopsies.
- Early-stage cancer detection, enabling timely intervention and treatment.